May 2020
  Research highlight
Diagnosing COVID-19-associated pulmonary aspergillosis.
There is increasing concern that patients with coronavirus disease 2019 (COVID-19) might be at risk of developing invasive pulmonary aspergillosis co-infection. This article highlights the key questions and knowledge gaps around COVID-19 associated invasive pulmonary aspergillosis (CAPA). It is crucial to gain insight into the interaction between Aspergillus spp and the SARS-CoV-2-infected lung. Such insights need to come from studies into diagnosis, prophylaxis and treatment, and immunology or host factors of CAPA.
Diagnosing COVID-19-associated pulmonary aspergillosis. Verweij et al., 2020
  News and notices
Advances Against Aspergillosis & Mucormycosis (2020, Lugano)

A playlist of talks from AAAM 2020, is now available on YouTube.
LIFE Worldwide Fungal Diagnsotics Webinars

LIFE Worldwide are offering FREE webinars in fungal diagnostics. Webinars are accredited by the Royal College of Pathology and attendees will earn 1 CPD credit per webinar. Webinars will take place on the first Wednesday of every month from 13:00 -14:00 BST, starting this week on 3rd June 2020.
  Research articles
Levels of evidence supporting clinical practice guidelines on invasive aspergillosis. Tejada et al., 2020.
This paper is the first study analysing the quality of evidence supporting invasive aspergillosis guidelines.  In evaluating the level of evidence (LOE) supporting recommendations in clinical practice guidelines (CPGs) of invasive aspergillosis (IA) it reports that among 238 strong recommendations, only 57 (24.0%) were supported by LOE A (multiple randomized controlled trial (RCT) or meta-analysis). When comparing recent CPGs with previous versions, the proportion of recommendations supported by LOE A did not significantly increase over time. The authors conclude that IA is a condition with an urgent unmet clinical need for more high-quality randomized trials.
Impact of high baseline Aspergillus-specific IgG levels on weight and quality-of-life outcomes of patients with chronic pulmonary aspergillosis. Bongomin et al., 2020.
This retrospective study evaluates the impact of quantitative baseline Aspergillus-specific immunoglobulin G (IgG) serum levels on weight changes of patients with chronic pulmonary aspergillosis (CPA) under antifungal treatment. A very high Aspergillus IgG may confer a higher likelihood of weight gain as a key, objective marker of clinical response, if patients can tolerate 12 months of antifungal therapy.
Clinical outcomes of patients with chronic pulmonary aspergillosis managed surgically. Setianingrum et al., 2020.
Surgical resection is one treatment modality for chronic pulmonary aspergillosis (CPA), and sometimes a preoperative presumption of lung cancer turns out to be CPA. This study audits surgical experience with regard to risk factors for relapse, and the value of postoperative monitoring of Aspergillus-immunogolubulin G (IgG) titres. It concludes that surgery in selected patients with CPA can have favourable outcomes. Relapse is common after surgical treatment of CPA but can be minimized with antifungal therapy, emphasizing the importance of an accurate diagnosis prior to surgery.
Club Cell TRPV4 Serves as a Damage Sensor Driving Lung Allergic Inflammation. Wiesner et al., 2020
Wiesner et al. show a secreted fungal protease allergen of humans induces inflammation in mice with hallmarks of allergic asthma. The protease damages junctions of bronchiolar epithelial club cells, which the mechanosensor and gated calcium channel TRPV4 detects. Calcineurin mediates the calcium signaling and cellular alarms initiating lung allergic inflammation.
Aspergillus Endophthalmitis: Clinical Presentations and Factors Determining Outcomes. Dave et al., 2020.
This retrospective, interventional, multicentric case series describes the clinical presentations, management and factors determining outcomes of Aspergillus endophthalmitis, an eye infection. It reports trauma and intraocular surgery as common causes. The common infecting fungi are Fusarium and Aspergillus species for exogenous endophthalmitis, the latter having high ocular morbidity and poor outcome.
  Veterinary article
Development of a comprehensive protein microarray for immunoglobulin E profiling in horses with severe asthma. White et al., 2019.
This study reports that protein microarrays can be used for large-scale IgE mapping of allergens associated with the environment of horses. This technology provides a sound platform for specific diagnosis, management, and treatment of severe equine asthma (SEA). SEA is a prevalent, performance-limiting disease associated with increased allergen-specific immunoglobulin E (IgE) against a range of environmental aeroallergens.
Diagnosis of severe respiratory infections in immunocompromised patients. Azoulay et al., 2020
This review focuses on the diagnosis of severe respiratory infections in immunocompromised patients. Special attention is given to newly validated diagnostic tests designed to be used on non-invasive samples or bronchoalveolar lavage fluid and capable of increasing the likelihood of an early etiological diagnosis.
Antifungal Therapy: New and Evolving Therapies. Nivoix et al., 2020
This article gives an overview of the mechanisms of action of currently used antifungals, as well as their spectrum of activity, clinically relevant pharmacological features, drug-drug interactions, and frequent side effects, all of which should inform the choice of agent when managing invasive fungal infections.
The Fungal Cell Wall: Candida, Cryptococcus, and Aspergillus Species. Garcia-Rubio et al., 2020
This paper reviews recent data on the composition and synthesis, influence of the components of the cell wall in fungi-host interaction and the role as a target for the next generation of antifungal drugs in yeasts and filamentous fungi (Aspergillus).
  Patients and carers
Maybe you or a loved one has just received a diagnosis of aspergillosis and you’re not sure where to start. Or maybe you need to share information about your condition with your doctor, carer, housing association or benefits assessor. Our patients and carers website can provide you with everything you need to know about aspergillosis. 
This month we focus on mental health during the coronavirus lockdown.
Further information on this, and other COVID-19 information is available on
Other meetings and support
We host a weekly video phone call with around 4-8 patients and a member of NAC staff each week. You can use a computer or mobile device to join the video but you need to register in advance. This meeting runs from 10:00-11:00 BST every Thursday.
To receive a text reminder when each meeting is approaching send us your mobile phone number (NB this doesn't operate in the US) to
Join our Facebook Groups
  • Our Aspergillosis Support Facebook Group has over 2000 members and is a safe place to meet and talk to other people with aspergillosis.
  • We also have a Facebook group for carers, friends and family of someone who is affected by the disease - join here
  • To find our regional and international groups, search for 'aspergillosis' in Facebook.
Clinical networks
Many conferences have been cancelled or postponed as a result of the Coronavirus pandemic. We advise you to check directly with the organisers of the conference you are interested in for the most up to date information. The conferences below are scheduled to proceed (correct at time of writing)
Veterinary Mycology Course, Romania7th to 11th September, 2020
54th Scientific Conference of the German Speaking Mycological Society. 3rd Interational Symposium of the CRC/Transregio FungiNet.Wurzburg, Germany 16th-19th September 2020
See more groups and societies
Visit our sites
(free online microscopy course)
(fungal education for clinicians)

Fungal Infection Trust, PO Box 482, Macclesfield, Cheshire SK10 9AR